Member Info for Yorkshirepragma

Thanks I missed this!
Gear was and prospects as ever...

At risk of answering own questions....Data on testing...oldish..see below.
Certainly testing in millions per day inevitable. Entering control regime phase will be higher:
Market....?.? Large ...very large

https://ourworldindata.org/covid-testing

Apologies...that’s strip ( linear flo/ pregnancy) type test strip...fingers

Any good research on market size of virus drip test? Must be several £bn globally??
Can’t find any estimates ...good or bad....
?....anyone?

Myles paper a great review. Perhaps he could consider a post Covid update?

Likely reference to ‘ novel reagents’ in their literature to simplify tests, are Affirmers. Source?

That’s affirmer...apologies

It’s important to recognise that the company have patent rights over process. Hence all partners have to share benefit.
Superb company, great team too.

TF, and a good choice too...stick with it

Referencing $6.5bn below, then likely similar ,or even higher sadly.

https://www.globenewswire.com/news-release/2019/08/28/1907833/0/en/Global-Home-Diagnostics-Market-is-Expected-To-Reach-USD-6-53-Billion-by-2025-Fior-Markets.html

Auto restraint from share movement ( up or down)

A block energy quote that...eh

I suspect they’ll need all the lab space at Wetherby for a while.

Affirmer also used in mRNA ‘delivery’ ,so novel immunology applications potentially vis COVID may be tried also?
I have invested here knowing some of the team and it’s intentions prior to this crisis ,and the unexpected potential for a significant revenue stream of many £m is clearly important.

More important at the moment is the technical capability of the team with will deliver ( as referenced by the quality of their partner companies) and how this will help a lot of people at this difficult time.
The Avacta Mc Nulty review paper ( recent) which can be found on this site ) gives a thorough and balanced position for those who need reassurance.

Best wishes to the Avacta team.

This is a highly capable company, scientifically and commercially.
Ss McNulty paper

Really appalling outcome as we know. BOD acted to achieve stretch objectives ,without challenge by internal members. Largely a 3 auzzie team all running without balance. Last FD must have challenged CF and been shown the door .
Not an honest game here methinks.later stage a total set of clouds . We will see where it goes ,but their part in this will be forever there. Karma...

Be a shame if this happens, especially with the effort to date.

http://etheses.whiterose.ac.uk/19759/

Ex Mc Nulty Twitter

Verification of potential vis Covid diagnostic??

That’s Affirmers! Apologies

https://mobile.twitter.com/MylesMcNulty/status/1238070782611337216

Affitprmers may allow good antibody specificity, swift development and reproducibility in lateral flow tests. I wonder?